DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

ClinicalTrials.gov ID: NCT00048074

Public ClinicalTrials.gov record NCT00048074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind Study Comparing the Effect of Different Treatment Regimens of Intravenous Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.

Study identification

NCT ID: NCT00048074
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 1,395 participants

Conditions and interventions

Conditions

Post Menopausal Osteoporosis

Interventions

ibandronate [Bonviva/Boniva] Drug

Drug

Eligibility (public fields only)

Age range: 55 Years to 80 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2002
Primary completion: Apr 30, 2005
Completion: Apr 30, 2005
Last update posted: Feb 2, 2016

2002 – 2005

United States locations

U.S. sites: 19
U.S. states: 17
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72205-7199	—
Not listed	Irvine	California	92618	—
Not listed	Rancho Mirage	California	92270	—
Not listed	Leesburg	Florida	34748	—
Not listed	Gainesville	Georgia	30501	—
Not listed	Coeur d'Alene	Idaho	83814	—
Not listed	Bethesda	Maryland	20817	—
Not listed	St Louis	Missouri	63110	—
Not listed	Billings	Montana	59120	—
Not listed	Omaha	Nebraska	68131	—
Not listed	Albuquerque	New Mexico	87106	—
Not listed	New York	New York	10029	—
Not listed	Bismarck	North Dakota	58503	—
Not listed	Fargo	North Dakota	58103	—
Not listed	Wyomissing	Pennsylvania	19610	—
Not listed	Rapid City	South Dakota	57701	—
Not listed	San Antonio	Texas	78229	—
Not listed	Virginia Beach	Virginia	23462	—
Not listed	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00048074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 2, 2016 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00048074 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →